Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Biodistribution of AGuIX Theranostic Nanoparticles Assessed by Magnetic Resonance Imaging in the NANORAD 2 Clinical Trial for Brain Metastases

  • By

  • Fabien Boux

  • Alexis Mercier

  • Daniela Talba

  • Jean-Yves Giraud

  • Sandrine Dufort

  • Khalide Seddik

  • Sylvie Grand

  • Mélanie Gataleta

  • Alexandre Leboucher

  • Johan Pietras

  • Olivier De Beaumont

  • Géraldine Le Duc

  • Camille Verry

  • April 4, 2026

Share

Original Source(s)

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

  • by Fabien Boux, Alexis Mercier, Daniela Talba, Jean-Yves Giraud, Sandrine Dufort, Khalide Seddik, Sylvie Grand, Mélanie Gataleta, Alexandre Leboucher, Johan Pietras, Olivier De Beaumont, Géraldine Le Duc, Camille Verry

  • April 4, 2026

Related Content

ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma

Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030

Screening Eligibility and Survival Among Patients With Lung Cancer in Korea